Ordering Recommendation

Supports clinical diagnosis of Alzheimer's disease (AD) in symptomatic individuals; for AD risk assessment only. Use to assess risk of amyloid-related imaging abnormalities (ARIA) when prescribing amyloid-targeted antibody treatments (e.g., lecanemab, donanemab). Pre- and post-test genetic counseling strongly recommended for informed consent and discussion of results.

New York DOH Approval Status

This test is New York state approved.

Specimen Required

Patient Preparation
Collect

Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).

Specimen Preparation

Transport 3 mL whole blood. (Min: 1 mL)

Storage/Transport Temperature

Refrigerated.

Unacceptable Conditions

Plasma or serum. Heparinized specimens. Frozen specimens in glass collection tubes.

Remarks

Testing of fetal specimens or specimens from patients under the age of 18 years is not offered.

Stability

Ambient: 72 hours; Refrigerated: 1 week; Frozen: 1 month.

Methodology

Polymerase Chain Reaction (PCR) / Fluorescence Monitoring

Performed

Varies

Reported

2-7 days

Reference Interval

Refer to report

Interpretive Data

Refer to Report

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Compliance Category

Laboratory Developed Test (LDT)

Note

Hotline History

N/A

CPT Codes

81401

Components

Component Test Code* Component Chart Name LOINC
2013338 APOE Specimen 31208-2
2013342 APOE Alzheimer Disease Risk, Genotype 42315-2
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.

Aliases

  • Alzheimer's
  • Alzheimers
  • APOE E4
  • ApoE 2 variants
  • ApoE Alzheimer Risk
  • ApoLipoprotein E Genotype
  • Lecanemab
  • Leqembi
  • ARIA
  • Donanemab
  • Kisunla
Apolipoprotein E (APOE) Genotyping, Alzheimer Disease Risk